These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6511252)

  • 1. Ultrasonic detection of red cell aggregation immediately preceding blood clotting.
    Sigel B; Machi J; Beitler JC; Ramos JR; Justin JR; Feinberg H
    Invest Radiol; 1984; 19(5):458-61. PubMed ID: 6511252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protamine-induced platelet aggregation and clotting investigated by ultrasound.
    Machi J; Sigel B; Feinberg H
    Haemostasis; 1987; 17(4):226-34. PubMed ID: 3114103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
    Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
    Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation protein function VI: augmentation of anticoagulant function by acetaldehyde-treated heparin.
    Brecher AS; Hellman K; Basista MH
    Dig Dis Sci; 1999 Jul; 44(7):1349-55. PubMed ID: 10489917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of red cell aggregation prevents spontaneous echocardiographic contrast formation in human blood.
    Fatkin D; Loupas T; Low J; Feneley M
    Circulation; 1997 Aug; 96(3):889-96. PubMed ID: 9264497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet aggregation following heparin and protamine administration.
    Ellison N; Edmunds LH; Colman RW
    Anesthesiology; 1978 Jan; 48(1):65-8. PubMed ID: 619707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of extreme acid and alkali changes upon the echogenicity of blood.
    Ramos JR; Sigel B; Machi J; Lu S; Levine MH; Hoover RP; Samuel SP; Robertson AL
    J Ultrasound Med; 1985 Oct; 4(10):513-8. PubMed ID: 4057343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red cell aggregation as a cause of blood-flow echogenicity.
    Sigel B; Machi J; Beitler JC; Justin JR
    Radiology; 1983 Sep; 148(3):799-802. PubMed ID: 6878705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulopathy screening in children with heparinized central venous catheters.
    Ellis MR
    Pediatrics; 1993 Jun; 91(6):1147-50. PubMed ID: 8502518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin neutralization by recombinant platelet factor 4 and protamine.
    Levy JH; Cormack JG; Morales A
    Anesth Analg; 1995 Jul; 81(1):35-7. PubMed ID: 7598278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects.
    Carr ME; Carr SL
    Thromb Res; 1994 Sep; 75(6):617-30. PubMed ID: 7831681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
    ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of erythrocyte aggregation by blood echogenicity: a preliminary study.
    Razavian SM; Levenson J; Peronneau P; Simon A
    J Cardiovasc Surg (Torino); 1995 Aug; 36(4):375-7. PubMed ID: 7593150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of regulating blood clotting with heparin and its antagonists on mast cells].
    Efimov VS; Rozkin MIa; Poberiĭ IA; Lindner DP
    Farmakol Toksikol; 1981; 44(1):80-5. PubMed ID: 7262304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin effect on red blood cell aggregation.
    Kameneva MV; Antaki JF; Watach MJ; Borovetz HS; Kormos RL
    Biorheology; 1994; 31(3):297-304. PubMed ID: 8729489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of immobilized protamine in removing heparin and preventing protamine-induced complications during extracorporeal blood circulation.
    Yang VC; Port FK; Kim JS; Teng CL; Till GO; Wakefield TW
    Anesthesiology; 1991 Aug; 75(2):288-97. PubMed ID: 1859016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can protamine be used during perfusion with heparin surface coated equipment?
    von Segesser LK; Gyurech DD; Schilling JJ; Marquardt K; Turina MI
    ASAIO J; 1993; 39(3):M190-4. PubMed ID: 8268526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of protamine of the prolonged response to intrapulmonary heparin.
    Wright CJ; Mahadoo J; Jaques LB
    Can J Surg; 1981 Mar; 24(2):130-2. PubMed ID: 7225967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal.
    DeLucia A; Wakefield TW; Andrews PC; Nichol BJ; Kadell AM; Wrobleski SK; Downing LJ; Stanley JC
    J Vasc Surg; 1993 Jul; 18(1):49-58; discussion 58-60. PubMed ID: 8326659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.